Mithramycin reduces expression of fibro-proliferative mRNAs in human gingival fibroblasts

Cell Proliferation

Volumn 44, Issue 2, 2011, Pages 166-173

  Fajardo, O A ^a   Thompson, K ^a,b   Parapuram, S K ^a   Liu, S ^a   Leask, A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Fanshawe College   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; MESSENGER RNA; MITHRAMYCIN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN P300; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; EXTRACELLULAR MATRIX; FIBROBLAST; GINGIVA; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; FIBROBLASTS; GINGIVA; HUMANS; MULTIGENE FAMILY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P300-CBP TRANSCRIPTION FACTORS; PLICAMYCIN; RNA, MESSENGER; SMAD3 PROTEIN; SP1 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 79952683311     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2011.00738.x     Document Type: Article

References (26)

1. Laurent GJ, Chambers RC, Hill MR, McAnulty RJ (2007) Regulation of matrix turnover: fibroblasts, forces, factors and fibrosis. Biochem. Soc. Trans. 35, 647-651.
2. Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117, 524-529.
3. Leask A (2009) Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma. Front. Biosci. (Elite Ed.) 1, 115-122.
4. Verrecchia F, Rossert J, Mauviel A (2001) Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis. J. Invest. Dermatol. 116, 755-763.
5. Holmes A, Abraham DJ, Chen Y, Shi-wen X, Denton C, Black CM et al. (2003) Sp1 is required for elevated CTGF expression in scleroderma fibroblasts. J. Biol. Chem. 278, 41728-41733.
6. Ihn H, Ihn Y, Trojanowska M (2001) Sp1 phosphorylation induced by serum stimulates the human alpha2(I) collagen gene expression. J. Invest. Dermatol. 117, 301-308.
7. Jimenez SA, Varga J, Olsen A, Li L, Diaz A, Herhal J et al. (1994) Functional analysis of human alpha 1(I) procollagen gene promoter. Differential activity in collagen-producing and -nonproducing cells and response to transforming growth factor beta 1. J. Biol. Chem. 269, 12684-12691.
8. Kum YS, Kim KH, Park TI, Suh IS, Oh HK, Cho CH et al. (2007) Antifibrotic effect via the regulation of transcription factor Sp1 in lung fibrosis. Biochem. Biophys. Res. Commun. 363, 368-374.
9. Ramirez F, Tanaka S, Bou-Gharios G (2006) Transcriptional regulation of the human alpha2(I) collagen gene (COL1A2), an informative model system to study fibrotic diseases. Matrix Biol. 25, 365-372.
10. Hitraya EG, Varga J, Artlett CM, Jimenez SA (1998) Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum. 41, 2048-2058.
11. Lumachi F, Brunello A, Roma A, Basso U (2009) Cancer-induced hypercalcemia. Anticancer Res. 29, 1551-1555.
12. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM (1991) Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest. 88, 1613-1621.
13. Sandorfi N, Louneva N, Hitraya E, Hajnoczky G, Saitta B, Jimenez SA (2005) Inhibition of collagen gene expression in systemic sclerosis dermal fibroblasts by mithramycin. Ann. Rheum. Dis. 64, 1685-1691.
14. Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM et al. (2007) Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum. 56, 4189-4194.
15. Huang da W, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J et al. (2007) The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8, R183.
16. Liu S, Kapoor M, Leask A (2009) Rac1 expression by fibroblasts is required for tissue repair in vivo. Am. J. Pathol. 174, 1847-1856.
17. Leask A, Parapuram SK, Shi-Wen X, Abraham DJ (2009) Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J. Cell Commun. Signal. 3, 89-94.
18. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A (2001) CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J. Biol. Chem. 276, 10594-10601.
19. Bhattacharyya S, Ghosh AK, Pannu J, Mori Y, Takagawa S, Chen G et al. (2005) Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum. 52, 1248-1258.
20. Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J. 18, 816-827.
21. Van Beek JP, Kennedy L, Rockel JS, Bernier SM, Leask A (2006) The induction of CCN2 by TGFbeta1 involves Ets-1. Arthritis Res. Ther. 8, R36.
22. Bomont P, Maddox P, Shah JV, Desai AB, Cleveland DW (2005) Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F. EMBO J. 24, 3927-3939.
23. Noh SJ, Li Y, Xiong Y, Guan KL (1999) Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. Cancer Res., 59, 558-564.
24. Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K (2006) Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology 45, 157-165.
25. Yang TP, Chiou HL, Maa MC, Wang CJ (2010) Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem. Biol. Interact. 183, 181-186.
26. Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X et al. (2010) Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 70, 1111-1119.